WO2005004926A1 - 樹状細胞浸潤能活性化組成物及び免疫賦活剤 - Google Patents
樹状細胞浸潤能活性化組成物及び免疫賦活剤 Download PDFInfo
- Publication number
- WO2005004926A1 WO2005004926A1 PCT/JP2003/008720 JP0308720W WO2005004926A1 WO 2005004926 A1 WO2005004926 A1 WO 2005004926A1 JP 0308720 W JP0308720 W JP 0308720W WO 2005004926 A1 WO2005004926 A1 WO 2005004926A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dendritic cells
- cells
- activating
- retinoic acid
- cis
- Prior art date
Links
- 210000004443 dendritic cell Anatomy 0.000 title claims abstract description 159
- 230000003213 activating effect Effects 0.000 title claims abstract description 51
- 239000000203 mixture Substances 0.000 title claims abstract description 30
- 239000012190 activator Substances 0.000 title claims 2
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 29
- 150000004492 retinoid derivatives Chemical class 0.000 claims abstract description 29
- 201000011510 cancer Diseases 0.000 claims abstract description 20
- 208000035473 Communicable disease Diseases 0.000 claims abstract description 9
- 241001465754 Metazoa Species 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims description 44
- 230000008595 infiltration Effects 0.000 claims description 43
- 238000001764 infiltration Methods 0.000 claims description 43
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 28
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 28
- 229930002330 retinoic acid Natural products 0.000 claims description 28
- 230000003308 immunostimulating effect Effects 0.000 claims description 27
- 239000003022 immunostimulating agent Substances 0.000 claims description 22
- 229960001438 immunostimulant agent Drugs 0.000 claims description 21
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 18
- 241000124008 Mammalia Species 0.000 claims description 18
- 230000036039 immunity Effects 0.000 claims description 13
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 claims description 10
- 229960005280 isotretinoin Drugs 0.000 claims description 10
- 230000004709 cell invasion Effects 0.000 claims description 8
- 230000004936 stimulating effect Effects 0.000 claims description 8
- -1 13-cis-retinoyl Chemical compound 0.000 claims description 5
- FPIPGXGPPPQFEQ-HWCYFHEPSA-N 13-cis-retinol Chemical compound OC/C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-HWCYFHEPSA-N 0.000 claims description 4
- 229940100609 all-trans-retinol Drugs 0.000 claims description 4
- 239000011717 all-trans-retinol Substances 0.000 claims description 4
- 235000019169 all-trans-retinol Nutrition 0.000 claims description 4
- FPIPGXGPPPQFEQ-DPZDGVIMSA-N dihydroretinol Natural products CC(=CCO)C=CC=C(C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-DPZDGVIMSA-N 0.000 claims description 4
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 125000001444 retinoyl group Chemical group O=C([*])/C([H])=C(C([H])([H])[H])/C([H])=C([H])/C([H])=C(C([H])([H])[H])/C([H])=C([H])/C1=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])C1(C([H])([H])[H])C([H])([H])[H] 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 230000002265 prevention Effects 0.000 abstract description 5
- 208000015181 infectious disease Diseases 0.000 abstract description 2
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 abstract 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 52
- 206010021143 Hypoxia Diseases 0.000 description 24
- 239000002609 medium Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- 239000000427 antigen Substances 0.000 description 15
- 102000036639 antigens Human genes 0.000 description 15
- 108091007433 antigens Proteins 0.000 description 15
- 230000001146 hypoxic effect Effects 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 13
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 229960001727 tretinoin Drugs 0.000 description 12
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 11
- 239000001301 oxygen Substances 0.000 description 11
- 229910052760 oxygen Inorganic materials 0.000 description 11
- XWCYDHJOKKGVHC-UHFFFAOYSA-N Vitamin A2 Chemical compound OCC=C(C)C=CC=C(C)C=CC1=C(C)C=CCC1(C)C XWCYDHJOKKGVHC-UHFFFAOYSA-N 0.000 description 10
- 230000004069 differentiation Effects 0.000 description 10
- 210000005087 mononuclear cell Anatomy 0.000 description 10
- 230000007959 normoxia Effects 0.000 description 10
- 229960003471 retinol Drugs 0.000 description 10
- 239000011607 retinol Substances 0.000 description 10
- 235000020944 retinol Nutrition 0.000 description 10
- 230000007954 hypoxia Effects 0.000 description 9
- 210000001165 lymph node Anatomy 0.000 description 9
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 8
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 8
- 230000002093 peripheral effect Effects 0.000 description 7
- 238000003753 real-time PCR Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 241000283707 Capra Species 0.000 description 5
- 206010033128 Ovarian cancer Diseases 0.000 description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 description 5
- DPRNENKPXAZQBI-UHFFFAOYSA-N alpha-Vitamin A Natural products OCC=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C DPRNENKPXAZQBI-UHFFFAOYSA-N 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 208000003174 Brain Neoplasms Diseases 0.000 description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 206010060862 Prostate cancer Diseases 0.000 description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102100040247 Tumor necrosis factor Human genes 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 201000004101 esophageal cancer Diseases 0.000 description 4
- 238000007804 gelatin zymography Methods 0.000 description 4
- 239000000411 inducer Substances 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 208000014018 liver neoplasm Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 201000008968 osteosarcoma Diseases 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- SHGAZHPCJJPHSC-JPXMXQIXSA-N 11-cis-retinoic acid Chemical class OC(=O)/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-JPXMXQIXSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 241000283086 Equidae Species 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 description 3
- 229930002945 all-trans-retinaldehyde Natural products 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 230000002797 proteolythic effect Effects 0.000 description 3
- 239000011604 retinal Substances 0.000 description 3
- 235000020945 retinal Nutrition 0.000 description 3
- 230000002207 retinal effect Effects 0.000 description 3
- NCYCYZXNIZJOKI-OVSJKPMPSA-N retinal group Chemical group C\C(=C/C=O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 206010046766 uterine cancer Diseases 0.000 description 3
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 206010061692 Benign muscle neoplasm Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102100035793 CD83 antigen Human genes 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 description 2
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- 102000003816 Interleukin-13 Human genes 0.000 description 2
- 108090000176 Interleukin-13 Proteins 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 201000004458 Myoma Diseases 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- 102000005406 Tissue Inhibitor of Metalloproteinase-3 Human genes 0.000 description 2
- 108010031429 Tissue Inhibitor of Metalloproteinase-3 Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 description 1
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
- 241000321096 Adenoides Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000797758 Homo sapiens C-C motif chemokine 7 Proteins 0.000 description 1
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 1
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- PVNJLUVGTFULAE-UHFFFAOYSA-N [NH4+].[Cl-].[K] Chemical compound [NH4+].[Cl-].[K] PVNJLUVGTFULAE-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 210000002534 adenoid Anatomy 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 229960001445 alitretinoin Drugs 0.000 description 1
- VBIXEXWLHSRNKB-UHFFFAOYSA-N ammonium oxalate Chemical compound [NH4+].[NH4+].[O-]C(=O)C([O-])=O VBIXEXWLHSRNKB-UHFFFAOYSA-N 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229940030156 cell vaccine Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 108700014844 flt3 ligand Proteins 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 208000025440 neoplasm of neck Diseases 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000012557 regeneration buffer Substances 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a composition for activating dendritic cell infiltration ability, an immunostimulant, and the like.
- tumor immunotherapy has included immunostimulation therapy that administers interleukin-1 2 (IL-2), etc., lymphokine-activated killer cells (LAK) derived from patient's peripheral lymphocytes, and tumor-infiltrating lymphocytes.
- IL-2 interleukin-1 2
- LAK lymphokine-activated killer cells
- Various immunotherapies have been attempted, such as adoptive immunotherapy infusing (TIL) and missile therapy using anti-tumor antigen monoclonal antibodies.
- TIL adoptive immunotherapy infusing
- gene therapy for cancer is also being actively conducted.
- cancer immunity is induced by transplanting cancer cells into which site force-in genes such as granulocyte macrophage colony stimulating factor (GM-CSF) have been introduced.
- GM-CSF granulocyte macrophage colony stimulating factor
- cell vaccine therapy to treat cancer has attracted attention.
- dendritic cells are known as typical antigen presenting cells.
- Dendritic cells are dendritic cell populations derived from hematopoietic stem cells and are widely distributed in living organisms. Activation of helper T cells depends on antigen presentation by dendritic cells, and dendritic cells are thought to capture antigens in peripheral blood, migrate to lymph nodes, and eventually mature in lymph nodes Has been.
- immature dendritic cells have a high ability to take in foreign substances serving as antigens and digest the antigens, but have a low ability to present antigens.
- mature dendritic cells are known to have low antigen uptake capacity but high antigen presentation ability.
- immature immature dendritic cells take up foreign substances, digest the foreign substances in the cells, and the mature dendritic cells differentiated by the stimulation present a part of the digested foreign substances outside the cells. Therefore, it is thought that specific antigen information is transmitted to lymphocytes.
- dendritic cells are known to be derived from bone marrow hematopoietic stem cells. Dendritic cell progenitors and immature dendritic cells are present in blood and lymphocytes. In addition, mature dendritic cells are present in the spleen and lymph nodes. It is known that peripheral monocytes are differentiated into immature dendritic cells when stimulated with granulocyte core stimulating factor (GM-CSF) or interleukin-14 (IL-4). It is known that immature dendritic cells differentiate into mature dendritic cells when stimulated with tumor necrosis factor (TNF).
- GM-CSF granulocyte core stimulating factor
- IL-4 interleukin-14
- dendritic cells When a foreign body enters a living body, dendritic cells have the function of phagocytosing the foreign body and presenting an antigen to T cells, and the T cell presented with the antigen phagocytoses the antigen. To perform such a function, the dendritic cells migrate from peripheral tissues to the regional lymph nodes when a foreign body enters the living body, indicating that the foreign body has entered.
- MMP-9 matrix metaoral proteinase-9
- dendritic cells differentiated under hypoxic conditions cannot migrate from peripheral tissues to lymph nodes, and cannot exhibit the antigen presenting ability as described above. For this reason, since the antigen-presenting ability of dendritic cells is not exhibited in cancer cells, ⁇ cells cannot kill cancer cells.
- an object of the present invention is to provide a composition that enables dendritic cells produced in a state of low oxygen concentration such as cancer cells to migrate to lymph nodes, that is, a composition that activates ⁇ dendritic cell infiltration ability. Is to do.
- Another object of the present invention is to provide an immunostimulant. Disclosure of the invention
- the present inventors have conducted intensive studies to achieve the above object, and as a result, have found that retinoid activates the infiltration ability of dendritic cells, thereby completing the present invention.
- the present invention has been made based on the above findings, and provides a composition for activating dendritic cell infiltration ability, which contains retinoid.
- the present invention also provides a method for activating dendritic cell invasion, which comprises administering a retinoid to a mammal.
- the present invention provides a method for activating dendritic cell invasion, which comprises administering the above-described composition for activating dendritic cell infiltration to a mammal.
- the present invention also provides an immunostimulant containing retinoid.
- the present invention also provides an immunostimulating agent containing retinoid and dendritic cells.
- the present invention also provides a method for stimulating mammalian immunity, which comprises administering retinoid to mammalian cells.
- the present invention also provides a method for activating mammal immunity, which comprises administering the above-mentioned immunostimulant to a mammal.
- the present invention also provides a method for preventing and treating infectious diseases and cancer in animals, which comprises administering or using the composition for activating dendritic cell infiltration or the immunostimulant.
- FIG. 1 is a diagram showing the results of surface antigen analysis using a flow cytometer.
- FIG. 2 is a diagram showing the results of real-time PCR.
- Figure 3 shows the results of Western blot analysis.
- Figure 4 shows the results of the gelatin zymography method.
- Figure 5 shows the results of the gelatin zymography method.
- FIG. 6 is a diagram showing the results of real-time PCR.
- FIG. 7 is a graph showing the results of measuring the invasive activity of immature dendritic cells and mature dendritic cells.
- FIG. 8 is a graph showing the results of examining changes in the infiltration activity of dendritic cells by the TIMP-1 protein.
- FIG. 9 is a graph showing the results of measuring the mRNA concentration of MMP-9 in cells after the induction of differentiation.
- FIG. 10 shows the results of measuring the invasive activity of dendritic cells differentiated under hypoxia.
- the composition for activating a dendritic cell infiltration ability of the present invention contains a retinoid.
- the retinoide used in the composition for activating dendritic cell infiltration ability of the present invention include retinoic acid, retinal, retinol and fatty acid returol ester, and dehydroretinol, dehydrodolenol, and fatty acid denitrile. Hydroletur esters and the like can be mentioned.
- retinoic acid examples include the following isomers of retinoic acid, that is, all-trans retinoic acid, 13-cis retinoic acid, 11-cis retinoic acid, 91-cis retinoic acid, 3,4-dehydro retinoic acid, etc. Is mentioned.
- retinol examples include the following isomers of retinol, namely, all-trans-retino, 13-cis-retino, 11-cis-retino, 9-cis-retino, and 3,4-dehydro retinol. No. Because they are widely marketed, all-transretinol, 13-cis-retinol, all-trans-retinoic acid and 13-cis-retinoic acid are preferred.
- the content of retinoid in the composition for activating dendritic cell infiltration ability of the present invention is defined as an amount for activating dendritic cell infiltrating ability when administered to a required patient.
- the dosage to be administered to a patient is generally determined based on the patient's body surface area, body weight, medical condition, and the like.
- the dose of the composition for activating a dendritic cell infiltration ability of the present invention is about 2 O mg / m 2 to about 5 O mg Zm 2 as the amount of retinoid.
- the dosage is preferably changed depending on the administration method, the amount of excipients, and when other drugs are used in combination.
- composition for activating dendritic cell infiltration of the present invention can be administered parenterally, such as subcutaneously, intraperitoneally, intramuscularly, or intravenously.
- parenteral dosage forms include, for example, aqueous solutions containing an active agent and glucose or other known pharmaceutically acceptable excipients at a concentration of about 5% in an isotonic salt solution.
- Solubilizing agents such as cyclodextrin and other solubilizers known to those skilled in the art may be added as excipients.
- the immunostimulator of the present invention contains retinoid.
- retinoid used in the immunostimulant of the present invention, those used in the above-mentioned composition for activating a dendritic cell infiltration ability can be used.
- the content, dosage, dosage form, and the like of the retinoid in the immunostimulant are the same as those of the composition for activating adenoid cell infiltration described above.
- the composition for activating a dendritic cell infiltration ability and the immunostimulant of the present invention activate the dendritic cell infiltration ability by promoting the production of MMP-9 which is a protein required for dendritic cell infiltration. It has the effect of doing.
- the infiltration ability of dendritic cells is activated, and the migration of dendritic cells to lymph nodes is activated, thereby exerting an immunostimulatory effect. Due to these effects, the composition for activating dendritic cell infiltration and the immunostimulant of the present invention can be used for mammals (for example, mice, cats, dogs, cows, horses, sheep, goats, rabbits, and rabbits). Etc.).
- Various leukemias malignant lymphoma, overlying cancer, liver cancer, lung cancer, stomach cancer, colorectal cancer, osteosarcoma, malignant melanoma, malignant ciliated epithelium, sarcoma, ovarian cancer, uterine cancer, prostate cancer, esophageal cancer, neck tumor, brain tumor It can be used for the treatment and prevention of various cancers such as and the like, and infectious diseases caused by various viruses and bacteria.
- the immunostimulant of the present invention may further contain dendritic cells.
- Dendritic cells can be obtained by culturing mononuclear cells, which are precursor cells of dendritic cells.
- mononuclear cells which are precursor cells of dendritic cells.
- peripheral blood, bone marrow fluid, umbilical cord blood and the like can be used as a raw material for mononuclear cells which are precursor cells of dendritic cells.
- Dendritic cells used in the immunostimulator of the present invention may be mature or immature dendritic cells. For example, differentiation into mature cells can be induced by stimulating and culturing mononuclear cells with GM-CSF, IL-14 and TNF- ⁇ .
- Dendritic cells used in the immunostimulator of the present invention can be obtained by culturing the above mononuclear cells in the presence of a differentiation inducer.
- mononuclear cells of peripheral blood are used as raw materials for dendritic cells.
- Mononuclear cells, which are precursor cells of dendritic cells, can be collected by blood collection or the like, and can be separated and purified from the collected blood.
- the method for separating mononuclear cells from red blood cells is not particularly limited, and a conventionally known method is used.
- peripheral blood mononuclear cells can be treated with Ficoll-Paqul density gradients or lysates.
- a method that utilizes the output is generally used.
- blood cells can be separated by suspending them in a solution that selectively lyses adult red blood cells, such as ammonium potassium chloride, ammonium oxalate, and the like.
- an appropriate commercially available medium such as RPMI-1640 medium, Dulbecco's modified idal medium (DMEM), and Iskov medium (IMDM) can be used.
- Serum may be added to the medium.
- bovine serum fetal bovine serum, or human serum can be used.
- Serum-free culture may be used, but if necessary, bovine albumin (BSA :), human albumin (HSA), etc. may be added.
- the medium may contain appropriate antibiotics, antibodies, pinolevic acid (0.5: about ⁇ 5 mM), glutamine (0.5-5 mM), 2-mercaptoethanol
- a differentiation inducer is added to these media, and the cells are cultured at about 37 ° C in an atmosphere of about 5% carbon dioxide for about 5 to 21 days.
- the culturing days are preferably about 7 to 14 days.
- the culture temperature (34 to 38 ° C) and the gas mixture ratio carbon dioxide gas 2 to 10%, or nitrogen gas or oxygen gas can be appropriately mixed) can be set under appropriate conditions. it can.
- Cytokines can be used as the inducer. Any suitable site force input may be used, such as GM-CSF, IL-4, stem self-actor (SCF), interleukin-13 (IL-13), TNF-a, Flt3- Ligand and the like can be used.
- concentration of the above cytokine is preferably about 1 to 1000 ng / ml in the medium.
- Cytokines used for cultivation can use factors derived from xenogeneic animals such as mice, but it is preferable to use factors derived from humans.
- dendritic cells used in the immunostimulant of the present invention are used by inoculating humans, it is safer to eliminate cell proliferation. It is known that the proliferation ability of mononuclear cells is reduced by inducing differentiation, but it is preferable to heat-treat, irradiate, or treat with mitomycin C for safer use.
- irradiating X-rays place a container containing dendritic cells under the X-ray irradiator tube In this case, it is preferable to irradiate with a total radiation dose of about 1000 to 330 Rad.
- processing in My bets mycin C for example, by suspending the dendritic cells at a density of 1 to 3 X 1 0 7 cells Zm 1 to obtain a cell suspension, the cell suspension lm 1 per mitomycin C 2 5 Add at a ratio of ⁇ 50 g, and keep the temperature at 37 ° C for about 30 to 60 minutes.
- the heat treatment method for example, the dendritic cells were suspended in 1 X 1 0 7 cells / m about 1 to give a cell suspension, 2 0 minutes the cell suspension at a temperature of 5 0 ⁇ 6 5 ° C Perform a degree of heat treatment.
- the immunostimulant containing dendritic cells of the present invention described above activates the infiltration ability of dendritic cells by retinol, and exerts an immunostimulatory effect. Therefore, the immunostimulant is used for various leukemias, malignant lymphomas, knee cancers, liver cancers, lung cancers, gastric cancers, and the like in mammals (eg, mice, cats, dogs, cows, horses, sheep, goats, rabbits, and humans).
- Various cancers such as colorectal cancer, osteosarcoma, malignant melanoma, malignant ciliated epithelium, myoma, ovarian cancer, ovarian cancer, prostate cancer, esophageal cancer, cervical head tumor, brain tumor, etc., and infection by various viruses, bacteria, etc. Used for illness.
- the dosage of the immunostimulant containing dendritic cells depends on the patient's age, body weight, sex, type of cancer, progression of the cancer, symptoms, etc., and cannot be determined unconditionally. , per person patients, the amount such ⁇ cells becomes 1 XI 0 7 cells, and a method of administering over between 1 week 0.
- the method for activating the infiltration ability of dendritic cells of the present invention is characterized by administering a retinoid to a mammal.
- Retinoids used in the method of the present invention for activating the infiltration ability of dendritic cells include, for example, retinoic acid, retinal, retinol, and fatty acid reticle, and dehydroretinol, dehydroretinol, and fatty acid dehydroester. Dloretul ester and the like.
- retinoic acid examples include the following isomers of retinoic acid, that is, all-trans retinoic acid, 13-cis retinoic acid, 11-cis retinoic acid, 91-cis retinoic acid, 3,4-dehydro retinoic acid, etc. Is mentioned.
- retinol examples include the following isomers of retinol, namely, all-trans-retino-mono, 13-cis-retino-nole, 11-cis-retino-nore, 91-cis-retino-no-re, and 3,4-dehydro-retinol. Because it is widely marketed, all tigers Nsretinol, 13-cis-retinol, all-trans-retinoic acid and 13-cis-retinoic acid are preferred.
- the above-described ⁇ dendritic cell infiltration ability activating composition of the present invention can be used.
- Examples of the mammal to which the method for activating the invasion ability of dendritic cells of the present invention include mice, cats, dogs, cows, horses, sheep, goats, rabbits, and humans.
- the amount of retinoid used in the method of activating dendritic cell infiltration ability of the present invention is defined as an amount for activating dendritic cell infiltration ability when administered to a required patient. It is.
- the dosage to be administered to a patient is generally determined based on the patient's body surface area, weight, medical condition, and the like.
- the dose of the dendritic cells invasiveness activating composition of the present invention, as the amount of retinoid is about 2 O mg / m 2 ⁇ about 5 O mg / m 2 or so.
- the dosage is preferably changed depending on the method of administration, the amount of excipients, and when other drugs are used in combination. Parenteral administration, such as subcutaneous, intraperitoneal, intramuscular, or intravenous administration, is preferred.
- the production of MMP-9 which is a protein necessary for infiltration of dendritic cells, is promoted, and the infiltration ability of dendritic cells is activated. Activates the migration of dendritic cells to the lymph nodes and exerts an immunostimulatory effect.
- the method of the present invention for activating dendritic cell infiltration ability can be used for the above mammals, including various leukemias, malignant lymphomas, knee cancers, liver cancers, lung cancers, gastric cancers, colorectal cancers, osteosarcomas , Malignant melanoma, malignant ciliated epithelium, sarcoma, ovarian cancer, uterine cancer, prostate cancer, esophageal cancer, neck cancer, brain tumor and other cancers, and treatment of infectious diseases caused by various viruses, bacteria, etc. Can be used for prevention. That is, according to the present invention, there is provided a method for preventing and treating animal infectious diseases and cancer, which comprises administering or using the composition for activating dendritic cell infiltration ability of the present invention.
- the method for stimulating immunity according to the present invention is characterized in that a retinoid is administered to a mammal.
- Retinoids used in the method for stimulating immunity of the present invention include, for example, retinoic acid, retinal, retinol and fatty acid returol ester, as well as dehydroretinol, dehydroretinol, and fatty acid dehydrochlore. Tulle esters and the like.
- retinoic acid includes the following isomers of retinoic acid, namely, all-trans retinoic acid, 13-cis retinoic acid, 11-cis retinoic acid, 9-cis retinoic acid, and 3,4-dehydromonoretinoic acid. And the like.
- examples of retinol include the following isomers of retinol, that is, all-trans-retino-one, 13-cis-retino-one, 11-cis-retino-one, 9-cis-retino- /, and 3,4-dehydro-retinol.
- all-transretinol, 13-cis-retinol, all-trans-retinoic acid and 13-cis-retinoic acid are preferred.
- the above-described immunostimulator of the present invention can be used.
- the mammal to which the method for activating immunity of the present invention is applied includes the mammal to which the above-described method for activating the infiltration of ⁇ cells according to the present invention is applied.
- the amount of retinoid used, the administration method, and the like are the same as those of the method for activating dendritic cell invasion described above.
- MMP-9 which is a protein required for infiltration of dendritic cells
- the infiltration ability of dendritic cells is activated, and By activating the transfer to the lymph node, it exerts an immunostimulatory effect.
- the method for activating immunity of the present invention can be used for the above mammals, and can be used for various leukemias, malignant lymphomas, Teng cancer, liver cancer, lung cancer, gastric cancer, colorectal cancer, osteosarcoma, and malignant melanoma
- various cancers such as malignant ciliated epithelium, myoma, ovarian cancer, uterine cancer, prostate cancer, esophageal cancer, cervical head tumor, brain tumor, and infectious diseases caused by various viruses, bacteria, etc.
- a method for preventing or treating animal infectious diseases and cancer which comprises administering or using the immunostimulant of the present invention.
- Example 1 Example 1
- Peripheral mononuclear cells from healthy subjects were separated by Ficoll one-pack density mating centrifugation. Peripheral mononuclear cells, complete R PM 1 - in 1 6 4 0 medium, 2 X 1 0 6 was dispersed so that the cells Zm 1, 3 7 ° with adhesion cells by 1 hour at C Got. Non-adherent cells were removed by washing five times with RPMI-164 medium.
- Adherent cells were isolated from 100 U Um1 of GM—CSF and 100 U / m 1 of IL—4, 10% FBS, 25 mM HE PES, 2 mM L-glutamic acid, 50 ⁇
- a hypoxic condition 1% oxygen concentration, hereinafter referred to as a hypoxic condition means 1% oxygen Concentration condition
- normoxic condition 20% oxygen concentration, hereinafter referred to as normoxic condition means 20% oxygen concentration
- the first group was cultured for 1 S in a medium containing IL-14 and GM-CSF and used as immature dendritic cells.
- the second group was treated with LPS (1 ⁇ g / ml) for 1 day and used as mature dendritic cells.
- the surface antigen of the dendritic cells obtained in Example 1 was detected using a flow cytometer. Antigen detection was performed on immature and mature cells. The cells to be measured (5 ⁇ 10 5 cells) were analyzed using FITC-conjugated mouse monoclonal antibodies against CD83, CD80, CD14, HLA-ABC, HLA-DR, and human CD1. a and CD86 for 30 minutes at 4 ° C. The monoclonal antibody used was purchased from Immunotech. The cells were then washed twice with phosphate buffered saline (PBS, pH 7.0) to remove excess monoclonal antibody.
- PBS phosphate buffered saline
- Fig. 1 shows the results of surface antigen analysis using a flow cytometer.
- imD Cs represents immature fibrous cells.
- MDCs indicate mature dendritic cells.
- CD14 a marker for monocytes
- CD83 a dendritic cell marker
- the costimulatory molecules, CD80 and CD86 were expressed on immature dendritic cells and mature dendritic cells.
- HLA-DR, HLA-ABC and CDla were expressed on immature dendritic cells and mature dendritic cells.
- the immature and mature dendritic cells obtained in Example 1 were differentiated under hypoxic and normoxic conditions, and the expression of MMP-9 mRNA in each cell was examined by real-time PCR. . Differentiation under hypoxic condition and normoxic condition was performed at 1% oxygen concentration and 20% oxygen concentration, respectively, for 7 days using a culture chamber. The real-time PCR was performed as follows. The cells used were immature and mature dendritic cells from three donors. Total RNA was isolated from cells obtained by culturing (1 ⁇ 10 6 cells) using a trizol reagent (TRIZOLreagent, LIFE TECHNOLOGIES).
- Each RN ⁇ sample (2 ⁇ g) was converted to cDNA in a 50 ⁇ l reaction mixture containing 000 U of TaqMan Reverse transcription reagent.
- Three sets of each cDNA (10 ng) were amplified using the SYBR-Green PCR assay kit, and the sequences were determined using the ABI PRISM 7900HT sequence Detection System.
- FIG. 2 shows the results of real-time PCR.
- imDCs indicates immature dendritic cells
- mDCs indicates mature dendritic cells
- N indicates normoxia
- H indicates hypoxia.
- the immature dendritic cells and mature dendritic cells obtained in Example 1 were diluted with serum-free RPMI 1640 medium to 5 ⁇ 10 5 cells Zm 1 at 37 ° C.
- the culture was performed at low temperature for 24 hours under low oxygen condition and normal oxygen condition.
- the medium was centrifuged and the supernatant was collected and stored at -70 ° C.
- culture supernatants of dendritic cells with the same protein concentration were loaded on a 7.5 w / v polyacrylamide gel and subjected to SDS-PAGE. went.
- the medium of the human fibrosarcoma cell line HT1080 was used as a positive control (producing J3-actin).
- proteins were plotted on a ditrocellulose membrane (Bio-Red, Hercules, CA) by the semi-dry method. After usual blocking and washing, the membrane was incubated with a primary antibody against human MMP-9 at a concentration of 1 ⁇ g / ml for 1 hour at room temperature.
- the primary antibody used was a mouse polyclonal IgG raised against human MMP- 9
- the secondary antibody was a horseradish 'peroxidase-labeled mouse heron anti-mouse IgG (at a dilution of 1: 2000). H & L).
- To detect intracellular MMP-9 protein each cell lysate containing 15 g of protein was loaded and subjected to Western blot analysis. The membrane was incubated with peroxidase-labeled goat anti-mouse IgG and developed using an ECL detection kit (Amersham, Tokyo, Japan).
- Fig. 3 shows the results of stamplot analysis.As shown in Fig. 3, immature dendritic cells and mature dendritic cells differentiated under normoxic conditions were more likely than those differentiated under hypoxic conditions. It produced high levels of MMP-9 protein.
- Immature dendritic cells and mature dendritic cells cultured in Example 4 were subjected to a gelatin zymography method. The method will be described below.
- the assay was performed by electrophoresis in a polyacrylamide gel containing sodium dodecyl sulfate (SDS) and gelatin. Briefly, the culture supernatant, separated from the cell culture supernatant containing the same protein content, was mixed with 3x buffer and applied to a 10% wZv polyacrylamide gel containing 1 mg / ml gelatin. Performed an electric swim. After electrophoresis, the gel was incubated in 10 Om1 of regeneration buffer (2.5% Triton X-100 in deionized water) with stirring.
- SDS sodium dodecyl sulfate
- the Genore of 1 00m l develo pme nt buffer (0.1 5] ⁇ of a C 1, 50 mM of T ris- HC 1, 1 0 mM of C a C l 2, 0. 05 % of The mixture was incubated at 37 ° C. in NaN 3 ). The gel was stained with 0.5% Coniasia Blue R-250 40% methanol / 10% acetic acid solution for 1 hour at room temperature. Subsequently, decolorization was performed for 4 hours while occasionally changing the decolorizing solution (40% methanolic 10% acetic acid deionized aqueous solution). The proteolytic activity band was clearly seen as a clear band against the dark blue backdrop. As a positive control, the medium of human fibrosarcoma cell line HT 1080 was used.
- Example 1 The immature and mature dendritic cells obtained in Example 1 were differentiated under hypoxic and normoxic conditions, and TIMP, a specific inhibitor of MMP-9 in each cell, 1. Expression of TIMP-2 and TIMP-3 was examined by real-time PCR. The method was performed in the same manner as in Example 3. The primers of SEQ ID NO: 3 and SEQ ID NO: 4 as primers for TIMP-1; the primers of SEQ ID NO: 5 and SEQ ID NO: 6 as primers for TIMP-2; Those shown in SEQ ID NOs: 7 and 8 were used.
- FIG. 6 shows the results.
- FIG. 6 is a diagram showing the results of real-time PCR.
- TIMP-1 was expressed at a higher level in dendritic cells differentiated in hypoxia than in dendritic cells differentiated in normoxia.
- TIMP-2 and TIMP-3 were expressed at the same level in dendritic cells cultured in both normoxic and hypoxic conditions. Since TIMP-1 is a specific inhibitor of MMP-9, this result indicates that dendritic cells differentiated under hypoxic conditions have lower proteolytic activity than dendritic cells differentiated under normoxic conditions.
- Example 7 To have Example 7
- Matrigel was immobilized on a membrane passing through the upper and lower chambers using the Transwell Chamber method.After washing, dendritic cells were placed in the upper chamber, and immature dendritic cells were placed in the lower chamber. 100 ng / m 1 of recombinant human RANTE S, 100 ng / m 1 of recombinant human MCP-3 for mature dendritic cells, and count the number of cells that have migrated to the lower chamber Then, the activity of dendritic cell invasion was measured.
- FIG. 7 is a graph showing the results of measuring the invasive activity of immature dendritic cells and mature dendritic cells. As shown in FIG. 7, immature ⁇ cells and mature cells both had higher invasive activity when differentiated under normoxic condition than those differentiated under hypoxic condition.
- Example 8
- FIG. 8 shows the results.
- FIG. 8 is a graph showing the results of examining changes in the infiltration activity of dendritic cells by TIMP-1 protein.
- “+” indicates the result when the TIMP-1 protein was added, and “+” indicates the result when the TIMP-1 protein was not added.
- FIG. 8 it can be seen that the invasive activity of immature dendritic cells and mature dendritic cells differentiated in normoxia is reduced by the TIMP-1 protein.
- the invasive activity of immature dendritic cells and mature dendritic cells differentiated under hypoxic conditions was not altered by TIMP-1 protein.
- Example 1 Add the mature dendritic cells obtained in Example 1 to the culture medium so that all-trans retinoic acid has a concentration of 1 and add the culture medium for 3 days.Add all trans-retinoic acid to the culture medium to a concentration of 5%. The cells were cultured for 1 day, and then all trans-retinoic acid was added to the medium at a concentration of 1 and cultured for 2 days to differentiate the dendritic cells. After the induction of differentiation, the mRNA level of ⁇ -9 in the cells was measured. The results are shown in FIG. As shown in FIG. 9, the mRNA concentration of MMP-9 was increased by adding all-trans retinoic acid to the medium.
- Example 1 0 the mRNA concentration of MMP-9 was increased by adding all-trans retinoic acid to the medium.
- the mature dendritic cells obtained in Example 1 were cultured by adding all the trans retinoic acid to the medium at a concentration of 1 ⁇ to induce differentiation. Next, the same operation as in Example 7 was performed, and the activity of dendritic cell invasion was measured. The results are shown in FIG. FIG. 10 shows the results of measuring the invasive activity of ⁇ cells differentiated under hypoxia. As shown in FIG. 10, the infiltration ability of dendritic cells was improved by adding all-trans retinoic acid to the medium.
- the composition for activating a dendritic cell infiltration ability of the present invention exerts an immunostimulating effect and is also used for stimulating immunity in mammals. Further, the composition for activating a dendritic cell infiltration ability and the immunostimulant of the present invention can be used for prevention and treatment of infectious diseases and cancer in animals.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005503841A JPWO2005004926A1 (ja) | 2003-07-09 | 2003-07-09 | 樹状細胞浸潤能活性化組成物及び免疫賦活剤 |
EP03817419A EP1647256A4 (en) | 2003-07-09 | 2003-07-09 | COMPOSITION FOR ACTIVATING THE INFILABILITY OF DENDRITIC CELLS AND IMMUNE ACTIVATOR |
PCT/JP2003/008720 WO2005004926A1 (ja) | 2003-07-09 | 2003-07-09 | 樹状細胞浸潤能活性化組成物及び免疫賦活剤 |
AU2003248255A AU2003248255A1 (en) | 2003-07-09 | 2003-07-09 | Dendritic cell infiltrativity activating composition and immune activator |
US10/563,612 US20060275268A1 (en) | 2003-07-09 | 2003-07-09 | Compositions for activating the infiltration activity of dendritic cells, and immunopotentiating agents |
CA002531636A CA2531636A1 (en) | 2003-07-09 | 2003-07-09 | Compositions for activating the infiltration activity of dendritic cells and immunopotentiating agents |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2003/008720 WO2005004926A1 (ja) | 2003-07-09 | 2003-07-09 | 樹状細胞浸潤能活性化組成物及び免疫賦活剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005004926A1 true WO2005004926A1 (ja) | 2005-01-20 |
WO2005004926A8 WO2005004926A8 (ja) | 2005-06-30 |
Family
ID=34044597
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/008720 WO2005004926A1 (ja) | 2003-07-09 | 2003-07-09 | 樹状細胞浸潤能活性化組成物及び免疫賦活剤 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20060275268A1 (ja) |
EP (1) | EP1647256A4 (ja) |
JP (1) | JPWO2005004926A1 (ja) |
AU (1) | AU2003248255A1 (ja) |
CA (1) | CA2531636A1 (ja) |
WO (1) | WO2005004926A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6966665B2 (en) | 2003-06-27 | 2005-11-22 | S. C. Johnson & Son, Inc. | Flameless candle with air intake chamber and air outflow chamber |
JP2009521409A (ja) * | 2005-12-08 | 2009-06-04 | ユニバーシティー オブ ルーイビル リサーチ ファンデーション,インコーポレーテッド | 制御性t細胞を増殖する方法と組成物 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05163160A (ja) * | 1991-12-13 | 1993-06-29 | Snow Brand Milk Prod Co Ltd | 免疫低下に伴う感染症の予防及び治療用栄養剤 |
JPH06192073A (ja) * | 1992-12-24 | 1994-07-12 | Eisai Co Ltd | 細胞分化誘導剤 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0918847A2 (en) * | 1996-08-14 | 1999-06-02 | Nexell Therapeutics Inc. | Cytokine-free culture of dendritic cells |
WO1999062537A1 (en) * | 1998-06-04 | 1999-12-09 | The Rockefeller University | Methods and agents for modulating the immune response and inflammation involving monocyte and dendritic cell membrane proteins |
-
2003
- 2003-07-09 EP EP03817419A patent/EP1647256A4/en not_active Withdrawn
- 2003-07-09 AU AU2003248255A patent/AU2003248255A1/en not_active Abandoned
- 2003-07-09 JP JP2005503841A patent/JPWO2005004926A1/ja active Pending
- 2003-07-09 WO PCT/JP2003/008720 patent/WO2005004926A1/ja not_active Application Discontinuation
- 2003-07-09 CA CA002531636A patent/CA2531636A1/en not_active Abandoned
- 2003-07-09 US US10/563,612 patent/US20060275268A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05163160A (ja) * | 1991-12-13 | 1993-06-29 | Snow Brand Milk Prod Co Ltd | 免疫低下に伴う感染症の予防及び治療用栄養剤 |
JPH06192073A (ja) * | 1992-12-24 | 1994-07-12 | Eisai Co Ltd | 細胞分化誘導剤 |
Non-Patent Citations (2)
Title |
---|
CHIRIVA-INTERNATI MAURIZIO ET AL.: "Expression of surface CD40 and immunocytochemical actin-bundling protein fascin in dendritic cells from multiple myeloma treated with retinoids during their differentiation in vitro", IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY: ANIMAL, vol. 37, no. 10, 2001, pages 641 - 643, XP002971867 * |
See also references of EP1647256A4 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6966665B2 (en) | 2003-06-27 | 2005-11-22 | S. C. Johnson & Son, Inc. | Flameless candle with air intake chamber and air outflow chamber |
JP2009521409A (ja) * | 2005-12-08 | 2009-06-04 | ユニバーシティー オブ ルーイビル リサーチ ファンデーション,インコーポレーテッド | 制御性t細胞を増殖する方法と組成物 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2005004926A1 (ja) | 2006-08-24 |
CA2531636A1 (en) | 2005-01-20 |
AU2003248255A8 (en) | 2005-01-28 |
EP1647256A1 (en) | 2006-04-19 |
EP1647256A4 (en) | 2007-10-31 |
US20060275268A1 (en) | 2006-12-07 |
WO2005004926A8 (ja) | 2005-06-30 |
AU2003248255A1 (en) | 2005-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Shin et al. | Human periodontal ligament stem cells suppress T‐cell proliferation via down‐regulation of non‐classical major histocompatibility complex‐like glycoprotein CD 1b on dendritic cells | |
Luft et al. | Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E2 regulates the migratory capacity of specific DC subsets | |
Fenton et al. | Inflammatory cues enhance TGFβ activation by distinct subsets of human intestinal dendritic cells via integrin αvβ8 | |
Okamoto et al. | Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation | |
Han et al. | Evaluation of 3 clinical dendritic cell maturation protocols containing lipopolysaccharide and interferon-γ | |
CN103756963A (zh) | 一种体外扩增nk细胞的方法 | |
JP2008133296A (ja) | 免疫応答のアジュバントとしてのケモカイン | |
US20130323832A1 (en) | Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance | |
JP6449148B2 (ja) | 免疫抑制細胞作成方法、及び、免疫抑制細胞を含む組成物の使用方法 | |
Vernal et al. | Variability in the response of human dendritic cells stimulated with Porphyromonas gingivalis or Aggregatibacter actinomycetemcomitans | |
EP1998811B1 (en) | Immunotherapy for immune suppressed patients | |
JP5706317B2 (ja) | 細胞の誘導および促進方法 | |
Xia et al. | Heparin induces differentiation of CD1a+ dendritic cells from monocytes: phenotypic and functional characterization | |
US7964400B2 (en) | Immune potentiating compositions of cancer cells | |
RAMONER et al. | Activation of human dendritic cells by bacillus Calmette-Guerin | |
Nakano et al. | Chemokine CCL19 promotes type 2 T-cell differentiation and allergic airway inflammation | |
WO2005004926A1 (ja) | 樹状細胞浸潤能活性化組成物及び免疫賦活剤 | |
CN110585427B (zh) | 提高机体免疫力的组合物及在抗成人t细胞白血病或鼻咽癌中的应用 | |
CN101321861A (zh) | 采用降低的温度产生树突细胞的方法 | |
CN105473710B (zh) | 同源盒转录因子VentX调控人树突状细胞的分化和成熟 | |
CN113881632A (zh) | 一种提高dc细胞活性的细胞培养基及培养方法 | |
Talker et al. | Transcriptomic signature and metabolic programming of bovine classical and nonclassical monocytes indicate distinct functional specializations | |
CN112852732A (zh) | Dc细胞培养方法、培养基和基于dc治疗策略的药物及酪氨酸激酶抑制剂在制备其的应用 | |
EP1871872B1 (en) | Method for activating cd8 t cells | |
Nishibata et al. | Research Article Blockade of EP4 by ASP7657 Modulates Myeloid Cell Differentiation In Vivo and Enhances the Antitumor Effect of Radiotherapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 03827055.2 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1-2004-502071 Country of ref document: PH |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005503841 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2531636 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003817419 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003817419 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006275268 Country of ref document: US Ref document number: 10563612 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10563612 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2003817419 Country of ref document: EP |